tDCS Effects on Brain Plasticity in Aphasia Treatment
Launched by THE HONG KONG POLYTECHNIC UNIVERSITY · Jul 29, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the effects of combining a type of brain stimulation called transcranial Direct Current Stimulation (tDCS) with traditional speech therapy for people recovering from a specific type of language difficulty known as Broca's Aphasia, which often occurs after a stroke. The goal is to see if this combination can help the brain adapt and improve communication skills better than speech therapy alone. Researchers will use imaging techniques like MRI to monitor changes in the brain during the study.
To participate, individuals must be between the ages of 65 and 74, have had a single stroke affecting the left side of the brain, and be right-handed Cantonese speakers. They should also be able to understand instructions for tasks. Unfortunately, those with other neurological conditions, specific types of aphasia, or certain medical devices or conditions will not be eligible. Participants can expect to receive both tDCS and speech therapy while contributing to valuable research that may improve treatment for aphasia in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. History of a single unilateral left-hemispheric stroke,
- • 2. Right handedness
- • 3. Demonstrated features of Broca's Aphasia
- • 4. Cantonese speaker
- • 5. Comprehension sufficient to carry out tasks
- • 6. No history of other neurological diseases
- Exclusion Criteria:
- • 1. Aphasia due to reasons other than Stroke, Traumatic brain injury
- • 2. Bilateral or multiple brain lesions
- • 3. Wernicke's aphasia and other speech disorders, degenerative, psychiatric or metabolic disorders
- • 4. Deaf, blind, pregnant/ or preparing for pregnancy, cognitive issues, tattoos
- • 5. Have cochlear implants, pacemaker, surgical nails for bone fracture, artificial joints, dental braces, dentures
- • 6. Taking anti-depressant medications
About The Hong Kong Polytechnic University
The Hong Kong Polytechnic University (PolyU) is a leading institution in applied research and education, dedicated to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, PolyU focuses on conducting rigorous and ethically sound research to enhance understanding of medical interventions and improve patient outcomes. The university leverages its multidisciplinary expertise, state-of-the-art facilities, and collaboration with industry partners to facilitate groundbreaking studies that address pressing health challenges. Committed to fostering an environment of academic excellence, PolyU aims to translate research findings into practical solutions that benefit society and contribute to the global advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kowloon, , Hong Kong
Patients applied
Trial Officials
Min Ney Wong, PhD
Principal Investigator
The Hong Kong Polytechnic University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials